Investigational drug LCZ696 (Novartis), an angiotensin receptor neprilysin inhibitor (ARNI), is superior to angiotensin-converting enzyme (ACE) inhibitor alone in reducing the risks of death and of hospitalization for heart failure, according to data presented at the American Heart Association's (AHA) Scientific Sessions in Chicago.
The collective performance of U.S. hospitals on individual accountability measures is on the rise, according to a new report by The Joint Commission.
The solution to connecting streams of data in differing formats is a workflow system that can normalize data and track it to a plan member.
FDA has approved alemtuzumab (Lemtrada, Genzyme, A Sanofi Company) for the treatment of patients with relapsing forms of multiple sclerosis (MS).
The new combination hepatitis C drug ledipasvir/sofosbuvir (Harvoni, Gilead Sciences) has been found to be highly effective in treating patients with cirrhosis who have not benefited from previous therapies.
Many people who report an allergy to penicillin actually are not allergic to penicillin, according to a study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, in Atlanta.
Approximately half of all adults in the U.S. have one or more chronic health conditions, and 75% of health care costs are due to chronic illnesses. When psychosocial issues like depression, low income, or lack of social support are present, the impact on costs is even greater.
Opposition to the Affordable Care Act (ACA) may explain why two pairs of states had very different performance outcomes in the federally facilitated marketplace (FFM) during the first open enrollment period.
The shortage of saline solution among hospitals is ongoing and doesn’t appear to be resolving anytime soon, according to a quality executive with the American Society of Health-System Pharmacists (ASHP). In addition, safety concerns make it prohibitive for hospitals to compound their own solutions.
Healthcare executives are optimistic about telemedicine and actively pursuing telemedicine advancements despite reimbursement and regulatory challenges, according to a new survey of senior healthcare executives released today by Foley & Lardner LLP.
Annual screenings for long-term smokers aged 55 to 74 will now be covered by Medicare, the Centers for Medicare and Medicaid Services (CMS) announced on Nov. 10.
FDA has approved a first-of-its-kind, personalized blood test to predict the likelihood of organ rejection in children with liver or intestine transplants (Pleximmune). The test was developed by researchers at Children’s Hospital of Pittsburgh of UPMC to determine a personalized rejection-risk index with cell-based technology.
In the accountable care model, providers are rewarded for taking steps that produce the best results. Accountable care requires putting the primary care physician at the center, where he or she can focus on the patient’s overall health by coordinating care with other providers.
Considering the challenges they faced during the first open enrollment period, Consumer Operated and Oriented Plans (CO-OPs) overall are doing very well, having signed up some 450,000 members across the nation, or 18% of all ACA exchange plan enrollees to date.
News briefs of interest to MHE readers.
In the shift away from fee-for-service to coordinated care models, healthcare organizations are reaping benefits by bundling payments for particular episodes of care. While still in the early stages, bundled payments promise to save costs and improve quality, and have already improved communication and collaboration among major players along the continuum of care
Employer-sponsored healthcare benefits are not insulated from the changes taking place in the broader healthcare marketplace. However employers, particularly large employers, are attempting to drive the conversation and actions toward issues that are important to them. One of the best ways to do that is to pressure health plans to help them achieve their healthcare goals
espite the fact that approximately 2.74 million patients used anti-obesity drugs in 2011, according to information services company IMS Health, the majority of health plans are following the lead of the Centers for Medicare and Medicaid Services and not covering them.
Two goals of the Affordable Care Act (ACA) are to provide more Americans with health insurance and lower the overall cost of healthcare. Managed Healthcare Executive recently asked four stakeholders to share their thoughts on what the law has accomplished so far, and its future impact.
Hospitals and health plans need each other and can use this relationship to enable improvements that benefit both parties.
The U.S. Supreme Court, in a decision expected by July of 2015, will hear arguments on the legality of the federal tax subsidies available to low and moderate income consumers that are a key component of the Affordable Care Act (ACA).
Certain group health plans that don’t provide minimally-defined coverage for in-patient hospitalization services will be disallowed if they were purchased after Nov. 4, 2014, the U.S. Department of Treasury has announced.
FDA has approved ramucirumab (Cyramza, Eli Lilly) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
In many ways, autism is a nightmare condition for health plans. Its prevalence appears to be skyrocketing, it typically requires long-term treatment, diagnoses are being made at younger and younger ages, there is a plethora of therapies - some very expensive - and there's no cure.
Audits of Medicare Advantage (MA) plans and healthcare plans offering financial assistance as part of the Affordable Care Act (ACA) will be conducted by the Health and Human Services Office of Inspector General (OIG), according to the Center for Public Integrity.
A new study has found a greater bleeding risk associated with the use of dabigatran (Pradaxa, Boehringer Ingelheim) in patients with nonvalvular atrial fibrillation (AF) than that cited on initial FDA approval of the drug.
FDA has approved simeprevir (Olysio, Janssen) in combination with sofosbuvir (Sovaldi, Gilead) as an oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis infection in adults.
Rosuvastatin (Crestor, AstraZeneca), a cholesterol-lowering agent, is currently the most-prescribed drug among the 100 most-prescribed and best-selling drugs in the United States. In the past 12 months, new prescriptions and refills for rosuvastatin have been estimated to amount to 23.7 million.
The risk of moderate or severe exacerbations in patients with severe but stable chronic obstructive pulmonary disease (COPD) who receive tiotropium plus salmeterol has been found to be similar among subjects discontinuing inhaled glucocorticoids and subjects continuing their use. Nevertheless, in making decisions about maintenance therapy for these patients the effect of withdrawal of glucocorticoids on their symptoms and pulmonary function should be carefully considered.
While Republicans picked up seven seats in the U.S. Senate on Nov. 4 to assume a majority, recent good news surrounding the Affordable Care Act (ACA) will likely safeguard major aspects of it from GOP repeal.
